If such drugs can be developed, they might be less likely to be oncogenic for the reasons discussed, in contrast to ATP-competitive inhibitors. The feasibility of this approach has been shown by ...

All NSAIDs variably inhibit COX-1 and COX-2 and the mechanisms of inhibition fall into three broad categories, although there are exceptions. For example, nimesulide is a weak competitive ...